Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
PF-3758309, a pyrrolopyrimidine-based inhibitor of p21-activated kinase 4 (PAK4), has demonstrated preclinical anti-tumor activity. However, due to poor pharmacokinetics and off-target effects, it has not advanced to clinical use. In this study, we conducted a comprehensive multi-omics analysis, including proteomics, transcriptomics, and ubiquitinomics, to investigate the mechanism of PF-3758309 in HCT116 cells. Our results revealed that PF-3758309 promotes the degradation of RNA polymerase II subunit proteins (POLR2A/B/E) via the cullin-RING ligase pathway. This process is mediated by the E3 ubiquitin ligase DNA damage-binding protein 2 (DDB2), and is independent of PAK4. Furthermore, the small-molecule inhibitor MLN4924, which blocks NEDD8-activating enzyme, reversed the degradation of POLR2A/B/E, supporting the role of ubiquitin-proteasome pathways in this process. Functional assays confirmed that PF-3758309 inhibits tumor cell growth and migration by promoting ubiquitination-dependent degradation of POLR2A/B/E. These findings uncover a previously unrecognized mechanism of PF-3758309's anti-tumor activity and provide a basis for further investigation into its therapeutic potential.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379277 | PMC |
| http://dx.doi.org/10.1038/s41420-025-02677-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2.
Int J Biol Macromol
September 2025
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, China; Institute of Cell The
Despite its potential as a cancer immunotherapy, wild-type IL-2 is limited by dose-limiting toxicities, including vascular leak syndrome, and its strong activation of regulatory T cells (Tregs), which dampens anti-tumor immunity. These drawbacks are largely driven by IL-2's binding to IL-2Rα, and avoiding this interaction can reduce IL-2-associated toxicities, although it cannot completely eliminate them. To overcome these limitations, βγ-biased IL-2 variants (Non-α-IL-2) have been developed to selectively activate effector T and NK cells.
View Article and Find Full Text PDFENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med
August 2025
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA. Electronic address:
Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors.
View Article and Find Full Text PDFDendrobin A inhibits gastric cancer: Mechanistic insights supported by integrated evidence.
Phytomedicine
August 2025
Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, the Hainan Branch of National Clinical Research Center for Cancer, the First Affiliated Hospital, Hainan Medical University, Haikou 571199, China; Ke
Background: Traditional Chinese medicine (TCM) has shown anti-tumor potential, but its molecular mechanisms remain poorly understood. This integrated bioinformatics, network pharmacology, and experimental study investigated the anti-cancer effects and mechanisms of Dendrobin A, a pharmacologically active bibenzyl compound from Dendrobium nobile, in gastric cancer (GC).
Methods: Differentially expressed genes (DEGs) were identified through analysis of the TCGA-STAD dataset.
IFNα2b in combination with oncolytic adenovirus enhances antitumor activity against melanoma.
Int Immunopharmacol
September 2025
The Key Laboratory of Molecular Biology of Infectious Diseases designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, China. Electronic address:
Melanoma is an aggressive malignancy originating from melanocytes, marked by its high metastatic potential, severe malignancy, and poor prognosis. The primary clinical approach involves surgical resection, complemented by adjuvant therapies such as radiotherapy, chemotherapy, targeted therapies, and immunotherapies. In recent years, high-dose IFNα2b has emerged as a pivotal adjuvant therapy following surgery.
View Article and Find Full Text PDFSpatial and Functional Characterization of IL1RL1+ Mast Cells Reveals Immune Regulatory Roles in Renal Cancer.
Mol Cell Probes
September 2025
Department of Urology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453100, China. Electronic address:
Background: Interleukin-1 receptor-like 1 (IL1RL1, also known as ST2) plays a critical role in immune regulation. Pan-cancer analysis has revealed that IL1RL1 is closely associated with cellular immune functions; however, its role in clear cell renal cell carcinoma (ccRCC) and the tumor microenvironment (TME) remains poorly defined.
Methods: We analyzed IL1RL1 expression patterns using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.